Stockreport

Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away [Seeking Alpha]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF ALT secured $340M in cash, providing a 2.5-year runway to support late-stage clinical development and operational milestones. Despite FDA Breakthrough Therapy designa [Read more]